Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer

Annals of Oncology

Volumn 17, Issue 6, 2006, Pages 968-973

  Goto, A ^a   Yamada, Y ^a,b   Yasui, H ^a   Kato, K ^a   Hamaguchi, T ^a   Muro, K ^a   Shimada, Y ^a   Shirao, K ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NONE   (Japan)

Author keywords

Colorectal cancer; Irinotecan; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; COLONY STIMULATING FACTOR; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BODY SURFACE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; SURVIVORS; TEGAFUR; TREATMENT OUTCOME;

EID: 33646883433     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl066     Document Type: Article

References (29)

1. Punt CJA. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004; 15: 1453-1459.
2. Rothenberg ML, Meropol NJ, Poplin EA et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
3. Sargent DJ, Niedzwiecki D, O'Connell MJ et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144-145.
4. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-308.
5. Shirasaka T, Nakano K, Takechi T et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxy pyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1993; 56: 2602-2606.
6. Takechi T, Nakano K, Uchida J et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997; 39: 205-211.
7. Kato T, Shimamoto Y, Uchida J et al. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. Anticancer Res 2001; 21: 1705-1712.
8. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. Cancer 1993; 71: 493-509.
9. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-4009.
10. Taguchi T, Inuyama Y, Kanamaru R et al. [Phase I study of S-1. S-1 Study Group]. Gan To Kagaku Ryoho 1997; 24: 2253-2264.
11. Sugimachi K, Maehara Y, Horikoshi N et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999; 57: 202-210.
12. Hoff PM, Sadd ED, Ajani JA et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003; 9: 134-142.
13. Van Groeningen CJ, Peters GJ, Schornagel JH et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18: 2772-2779.
14. Ohtsu A, Baba N, Sakata Y et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 2000; 83: 141-145.
15. Shirao K, Ohtsu A, Takada H et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004; 100: 2355-2361.
16. Van den Brande J, Schöffski P, Schellens JHM et al. EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003; 88: 648-653.
17. Yamada Y, Yasui H, Goto A et al. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. Int J Clin Oncol 2003; 8: 374-380.
18. Therasse P, Arbuck SG, Eisenheuer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
19. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
20. Schalhorn A, Ludwig FW, Ouietzsch D et al. Phase III trial of irinotecan plus oxaliplatin (IROX) versus irnotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-trial. (Abstract) Proc ASCO 2005; 23: 250s.
21. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized controlled trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A mutticenter study of the groppo oncologico dell'italia meridionale. J Clin Oncol 2005; 23: 4866-4875.
22. Köhne CH, Van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European organization for research and treatment of cancer gastrointestinal group study 40986. J Clin Oncol 2005; 23: 4856-4865.
23. Brink HM, Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Doc Ophthalmol 1995; 90: 1-6.
24. Hassan A, Hurwitz JJ, Burkes RL. Epiphora in patients receiving systemic 5-fluorouracil therapy. Can J Ophthalmol 1998; 33: 14-19.
25. Narahara H, Takiuchi T, Tsujinaka H et al. Phase I study of CPT-11 plus S-1 in patients with metastatic gastric cancer. (Abstract) J Clin Oncol 2002; 21: 170.
26. Bajetta E, Di Bartolomeo M, Mariani L et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100: 279-287.
27. Patt YZ, Leibmann J, Diamandidis D et al. Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial. (Abstract) J Clin Oncol 2004; 22: 271.
28. Rea DW, Nortier JWR, Ten WW et al. A phase I/II and pharmacokinetics study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 2005; 16: 1123-1132.
29. Mackay HJ, Hill M, Twelves C et al. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2003; 14: 1264-1269.